However, importantly, patients with an overall low drug target profile all expressed distinct therapeutic targets that are currently being tested in clinical trials in melanoma and other cancer types (NCT03329950 [CD40]; NCT03809624 [PD-L1 X 4-1BB]; NCT04148937 [CD73]; NCT04144140 [STING]; NCT03894618 [OX40L]), suggesting different mechanisms of resistance and different treatment options for patients. Here, TNFSF4 is linked to cancer.